BCRX
Price
$7.64
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
97 days until earnings call
DNLI
Price
$29.63
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
109 days until earnings call
Ad is loading...

BCRX vs DNLI

Header iconBCRX vs DNLI Comparison
Open Charts BCRX vs DNLIBanner chart's image
BioCryst Pharmaceuticals
Price$7.64
Change-$0.00 (-0.00%)
Volume$1.31M
CapitalizationN/A
Denali Therapeutics
Price$29.63
Change-$0.00 (-0.00%)
Volume$1.59M
CapitalizationN/A
BCRX vs DNLI Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BCRX vs. DNLI commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and DNLI is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (BCRX: $7.64 vs. DNLI: $29.63)
Brand notoriety: BCRX: Notable vs. DNLI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 66% vs. DNLI: 184%
Market capitalization -- BCRX: $1.58B vs. DNLI: $4.27B
BCRX [@Biotechnology] is valued at $1.58B. DNLI’s [@Biotechnology] market capitalization is $4.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.77B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 6 bullish TA indicator(s).

  • BCRX’s TA Score: 3 bullish, 7 bearish.
  • DNLI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а -1.16% price change this week, while DNLI (@Biotechnology) price change was +0.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +5.54%.

Reported Earning Dates

BCRX is expected to report earnings on Feb 19, 2025.

DNLI is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($4.27B) has a higher market cap than BCRX($1.58B). DNLI YTD gains are higher at: 38.071 vs. BCRX (27.546).
BCRXDNLIBCRX / DNLI
Capitalization1.58B4.27B37%
EBITDAN/AN/A-
Gain YTD27.54638.07172%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
BCRX vs DNLI: Fundamental Ratings
BCRX
DNLI
OUTLOOK RATING
1..100
6812
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
93
Overvalued
PROFIT vs RISK RATING
1..100
6678
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
4538
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (3) in the Biotechnology industry is significantly better than the same rating for DNLI (93). This means that BCRX’s stock grew significantly faster than DNLI’s over the last 12 months.

BCRX's Profit vs Risk Rating (66) in the Biotechnology industry is in the same range as DNLI (78). This means that BCRX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as BCRX (100). This means that DNLI’s stock grew similarly to BCRX’s over the last 12 months.

DNLI's Price Growth Rating (38) in the Biotechnology industry is in the same range as BCRX (45). This means that DNLI’s stock grew similarly to BCRX’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as BCRX (100). This means that DNLI’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X90584.1640002628.351600
+2.99%
Bitcoin cryptocurrency
TSLA330.241.75
+0.53%
Tesla
AAPL225.120.89
+0.40%
Apple
SPY597.190.29
+0.05%
SPDR® S&P 500® ETF Trust
GME26.46-0.38
-1.42%
GameStop Corp

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with NKTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-2.30%
NKTX - BCRX
46%
Loosely correlated
-4.59%
PGEN - BCRX
43%
Loosely correlated
-3.57%
DNLI - BCRX
42%
Loosely correlated
-0.87%
ARDX - BCRX
42%
Loosely correlated
-1.96%
ATAI - BCRX
42%
Loosely correlated
-7.53%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.87%
BEAM - DNLI
64%
Loosely correlated
-1.57%
NTLA - DNLI
58%
Loosely correlated
-3.24%
ALEC - DNLI
57%
Loosely correlated
-7.66%
JANX - DNLI
55%
Loosely correlated
-1.61%
RCKT - DNLI
55%
Loosely correlated
-2.25%
More